INSILICO MEDICINE PARTNERS WITH US FIRM ON LONGEVITY AI

Insilico Medicine, known for applying machine learning to accelerate drug discovery, is expanding its focus to longevity research through the collaboration. The partnership represents the firm's commitment to leveraging AI technology beyond traditional pharmaceutical development. The company, operating as Insilico Medicine Cayman TopCo, has built a track record of using artificial intelligence to identify novel drug candidates and predict biological outcomes. This latest initiative channels that expertise toward understanding and potentially extending human healthspan and lifespan. The specifics of the US partnership, including timeline and funding details, have not been disclosed. The move aligns with growing industry interest in longevity science, where AI tools are increasingly deployed to analyze complex biological data and identify interventions that could slow aging processes. Insilico's expansion into longevity underscores how AI drug discovery platforms are diversifying applications across the biotech landscape.